CCR5预测car - t细胞治疗中的神经毒性。

IF 3.8 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2025-06-26 DOI:10.1111/bjh.20228

Ayal Rozenberg, Shahar Shelly, Raz Winer, Riva Fineman, Shani Haller, Shimrit Ringelstein-Harlev, Israel Henig, Dana Yehudai-Ofir, Tsila Zuckerman, Tamar Tadmor, Reut Harel, Esther Ganelin-Cohen, Ofrat Beyar-Katz

{"title":"CCR5预测car - t细胞治疗中的神经毒性。","authors":"Ayal Rozenberg, Shahar Shelly, Raz Winer, Riva Fineman, Shani Haller, Shimrit Ringelstein-Harlev, Israel Henig, Dana Yehudai-Ofir, Tsila Zuckerman, Tamar Tadmor, Reut Harel, Esther Ganelin-Cohen, Ofrat Beyar-Katz","doi":"10.1111/bjh.20228","DOIUrl":null,"url":null,"abstract":"<p>Patients undergoing chimeric antigen receptor T (CAR T)-cell therapy are at risk of developing immune effector cell-associated neurotoxicity syndrome (ICANS). We observed an upregulation of CCR5 and CCR2 expression in CD4+ T cells among patients who developed ICANS. Notably, increased CCR5 expression was detectable as early as day one post-infusion, but only in those who eventually developed ICANS, suggesting a potential role for CCR5 as an early biomarker for ICANS onset.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"207 3","pages":"1133-1137"},"PeriodicalIF":3.8000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436234/pdf/","citationCount":"0","resultStr":"{\"title\":\"CCR5 predicts neurotoxicity in CAR-T-cell therapy\",\"authors\":\"Ayal Rozenberg, Shahar Shelly, Raz Winer, Riva Fineman, Shani Haller, Shimrit Ringelstein-Harlev, Israel Henig, Dana Yehudai-Ofir, Tsila Zuckerman, Tamar Tadmor, Reut Harel, Esther Ganelin-Cohen, Ofrat Beyar-Katz\",\"doi\":\"10.1111/bjh.20228\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Patients undergoing chimeric antigen receptor T (CAR T)-cell therapy are at risk of developing immune effector cell-associated neurotoxicity syndrome (ICANS). We observed an upregulation of CCR5 and CCR2 expression in CD4+ T cells among patients who developed ICANS. Notably, increased CCR5 expression was detectable as early as day one post-infusion, but only in those who eventually developed ICANS, suggesting a potential role for CCR5 as an early biomarker for ICANS onset.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":\"207 3\",\"pages\":\"1133-1137\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436234/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bjh.20228\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.20228","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

接受嵌合抗原受体T （CAR - T）细胞治疗的患者有发生免疫效应细胞相关神经毒性综合征（ICANS）的风险。我们观察到在发生ICANS的患者中，CD4+ T细胞中CCR5和CCR2表达上调。值得注意的是，CCR5表达的增加早在输注后第一天就可以检测到，但仅在最终发展为ICANS的患者中，这表明CCR5作为ICANS发病的早期生物标志物的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

CCR5 predicts neurotoxicity in CAR-T-cell therapy

查看原文本刊更多论文

CCR5 predicts neurotoxicity in CAR-T-cell therapy

Patients undergoing chimeric antigen receptor T (CAR T)-cell therapy are at risk of developing immune effector cell-associated neurotoxicity syndrome (ICANS). We observed an upregulation of CCR5 and CCR2 expression in CD4+ T cells among patients who developed ICANS. Notably, increased CCR5 expression was detectable as early as day one post-infusion, but only in those who eventually developed ICANS, suggesting a potential role for CCR5 as an early biomarker for ICANS onset.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.